Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is BUDESONIDE USP, with a corresponding US DMF Number 27461.
Remarkably, this DMF maintains an Active status since its submission on March 31, 2014, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of June 01, 2015, and payment made on November 12, 2014, indicating their dedication to facilitating drug approvals, Categorized as Type II